vs
艾伯维（ABBV）与Pediatrix Medical Group, Inc.（MD）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是Pediatrix Medical Group, Inc.的33.7倍（$16.6B vs $493.8M）。艾伯维净利率更高（10.9% vs 6.8%，领先4.1%）。艾伯维同比增速更快（10.0% vs -1.7%）。过去两年艾伯维的营收复合增速更高（16.2% vs -0.1%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
Pediatrix Medical Group是美国领先的专科医疗服务提供商，核心业务覆盖母胎医学、新生儿科、儿科心脏病学等儿科亚专科领域，与美国各地医疗机构合作，为女性、新生儿及儿童提供循证专科医疗服务。
ABBV vs MD — 直观对比
营收规模更大
ABBV
是对方的33.7倍
$493.8M
营收增速更快
ABBV
高出11.7%
-1.7%
净利率更高
ABBV
高出4.1%
6.8%
两年增速更快
ABBV
近两年复合增速
-0.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $493.8M |
| 净利润 | $1.8B | $33.7M |
| 毛利率 | 72.6% | — |
| 营业利润率 | 27.3% | 9.9% |
| 净利率 | 10.9% | 6.8% |
| 营收同比 | 10.0% | -1.7% |
| 净利润同比 | 8354.5% | 10.5% |
| 每股收益（稀释后） | $1.02 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVMD
| Q4 25 | $16.6B | $493.8M | ||
| Q3 25 | $15.8B | $492.9M | ||
| Q2 25 | $15.4B | $468.8M | ||
| Q1 25 | $13.3B | $458.4M | ||
| Q4 24 | $15.1B | $502.4M | ||
| Q3 24 | $14.5B | $511.2M | ||
| Q2 24 | $14.5B | $504.3M | ||
| Q1 24 | $12.3B | $495.1M |
净利润ABBVMD
| Q4 25 | $1.8B | $33.7M | ||
| Q3 25 | $186.0M | $71.7M | ||
| Q2 25 | $938.0M | $39.3M | ||
| Q1 25 | $1.3B | $20.7M | ||
| Q4 24 | $-22.0M | $30.5M | ||
| Q3 24 | $1.6B | $19.4M | ||
| Q2 24 | $1.4B | $-153.0M | ||
| Q1 24 | $1.4B | $4.0M |
毛利率ABBVMD
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 70.0% | — | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | — | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 66.7% | — |
营业利润率ABBVMD
| Q4 25 | 27.3% | 9.9% | ||
| Q3 25 | 12.1% | 13.8% | ||
| Q2 25 | 31.7% | 12.8% | ||
| Q1 25 | 28.0% | 7.0% | ||
| Q4 24 | -9.9% | 7.8% | ||
| Q3 24 | 26.5% | 6.6% | ||
| Q2 24 | 27.6% | -31.3% | ||
| Q1 24 | 22.7% | 3.2% |
净利率ABBVMD
| Q4 25 | 10.9% | 6.8% | ||
| Q3 25 | 1.2% | 14.5% | ||
| Q2 25 | 6.1% | 8.4% | ||
| Q1 25 | 9.6% | 4.5% | ||
| Q4 24 | -0.1% | 6.1% | ||
| Q3 24 | 10.8% | 3.8% | ||
| Q2 24 | 9.5% | -30.3% | ||
| Q1 24 | 11.1% | 0.8% |
每股收益（稀释后）ABBVMD
| Q4 25 | $1.02 | $0.40 | ||
| Q3 25 | $0.10 | $0.84 | ||
| Q2 25 | $0.52 | $0.46 | ||
| Q1 25 | $0.72 | $0.24 | ||
| Q4 24 | $-0.03 | $0.37 | ||
| Q3 24 | $0.88 | $0.23 | ||
| Q2 24 | $0.77 | $-1.84 | ||
| Q1 24 | $0.77 | $0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $375.2M |
| 总债务越低越好 | $58.9B | $570.5M |
| 股东权益账面价值 | $-3.3B | $865.9M |
| 总资产 | $134.0B | $2.2B |
| 负债/权益比越低杠杆越低 | — | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资ABBVMD
| Q4 25 | $5.3B | $375.2M | ||
| Q3 25 | $5.7B | $340.1M | ||
| Q2 25 | $6.5B | $224.7M | ||
| Q1 25 | $5.2B | $99.0M | ||
| Q4 24 | $5.6B | $229.9M | ||
| Q3 24 | $7.3B | $103.8M | ||
| Q2 24 | $13.2B | $19.4M | ||
| Q1 24 | $18.1B | $8.0M |
总债务ABBVMD
| Q4 25 | $58.9B | $570.5M | ||
| Q3 25 | $63.0B | $577.2M | ||
| Q2 25 | $63.0B | $583.9M | ||
| Q1 25 | $64.5B | $590.5M | ||
| Q4 24 | $60.3B | $597.1M | ||
| Q3 24 | $58.5B | — | ||
| Q2 24 | $58.0B | — | ||
| Q1 24 | $63.8B | — |
股东权益ABBVMD
| Q4 25 | $-3.3B | $865.9M | ||
| Q3 25 | $-2.6B | $890.7M | ||
| Q2 25 | $-183.0M | $833.8M | ||
| Q1 25 | $1.4B | $789.2M | ||
| Q4 24 | $3.3B | $764.9M | ||
| Q3 24 | $6.0B | $732.5M | ||
| Q2 24 | $6.8B | $706.5M | ||
| Q1 24 | $8.0B | $856.2M |
总资产ABBVMD
| Q4 25 | $134.0B | $2.2B | ||
| Q3 25 | $133.9B | $2.2B | ||
| Q2 25 | $137.2B | $2.1B | ||
| Q1 25 | $136.2B | $2.0B | ||
| Q4 24 | $135.2B | $2.2B | ||
| Q3 24 | $143.4B | $2.1B | ||
| Q2 24 | $141.9B | $2.0B | ||
| Q1 24 | $148.9B | $2.2B |
负债/权益比ABBVMD
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.70× | ||
| Q1 25 | 45.44× | 0.75× | ||
| Q4 24 | 18.15× | 0.78× | ||
| Q3 24 | 9.70× | — | ||
| Q2 24 | 8.56× | — | ||
| Q1 24 | 7.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $114.1M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 2.0% | — |
| 现金转化率经营现金流/净利润 | 2.87× | 3.39× |
| 过去12个月自由现金流最近4个季度 | $17.8B | — |
8季度趋势，按日历期对齐
经营现金流ABBVMD
| Q4 25 | $5.2B | $114.1M | ||
| Q3 25 | $7.0B | $137.3M | ||
| Q2 25 | $5.2B | $137.2M | ||
| Q1 25 | $1.6B | $-117.5M | ||
| Q4 24 | $7.0B | $133.0M | ||
| Q3 24 | $5.4B | $91.8M | ||
| Q2 24 | $2.3B | $107.0M | ||
| Q1 24 | $4.0B | $-125.2M |
自由现金流ABBVMD
| Q4 25 | $4.9B | — | ||
| Q3 25 | $6.6B | — | ||
| Q2 25 | $4.9B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $6.8B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $3.8B | — |
自由现金流率ABBVMD
| Q4 25 | 29.4% | — | ||
| Q3 25 | 42.1% | — | ||
| Q2 25 | 31.7% | — | ||
| Q1 25 | 10.5% | — | ||
| Q4 24 | 44.7% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 14.0% | — | ||
| Q1 24 | 31.3% | — |
资本支出强度ABBVMD
| Q4 25 | 2.0% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 1.6% | — |
现金转化率ABBVMD
| Q4 25 | 2.87× | 3.39× | ||
| Q3 25 | 37.76× | 1.91× | ||
| Q2 25 | 5.49× | 3.49× | ||
| Q1 25 | 1.27× | -5.66× | ||
| Q4 24 | — | 4.36× | ||
| Q3 24 | 3.49× | 4.72× | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | -31.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
